The role of trastuzumab in the management of HER2-positive metastatic breast cancer: An updated review

Breast Cancer

Volumn 16, Issue 4, 2009, Pages 295-300

  Tokuda, Yutaka ^a   Suzuki, Yasuhiro ^a   Saito, Yuki ^a   Umemura, Shinobu ^a  

^a TOKAI UNIVERSITY   (Japan)

Author keywords

HER2 positive; Metastatic breast cancer; Trastuzumab

Indexed keywords

AMRUBICIN; ANASTROZOLE; CAPECITABINE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ETOPOSIDE; HORMONE RECEPTOR; LAPATINIB; METHOTREXATE; NAVELBINE; PACLITAXEL; TAXANE DERIVATIVE; THIOTEPA; TRASTUZUMAB; VINBLASTINE;

ALOPECIA; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DRUG TREATMENT FAILURE; HEART FUNCTION; HORMONAL THERAPY; HUMAN; LOADING DRUG DOSE; METASTASIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; HUMANS; NEOPLASM METASTASIS; RECEPTOR, ERBB-2;

EID: 70349687134     PISSN: 13406868     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12282-009-0142-8     Document Type: Review

References (22)

1. M Ohta Y Tokuda Y Suzuki M Kubota T Watanabe H Fujii Y Sasaki T Niwa H Makuuchi T Tajima 2001 A case with HER2-overexpressing breast cancer completely responded to humanized anti-HER2 monoclonal antibody Jpn J Clin Oncol 31 553 556 11773264 10.1093/jjco/hye119 1:STN:280:DC%2BD38%2FkvFSrtQ%3D%3D
2. National Comprehensive Cancer Network (NCCN) http://www.nccn.org/ professionals/physician-gls/default.asp.
3. RJ Pietras J Arboleda DM Reese N Wongvipat MD Pegram L Ramos CM Gorman MG Parker MX Sliwkowski DJ Slamon 1995 HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells Oncogene 10 2435 2446 7784095 1:CAS:528:DyaK2MXmsFCgtr4%3D
4. C Carlomagno F Perrone C Gallo M De Laurentiis R Lauria A Morabito G Pettinato L Panico A D'Antonio AR Bianco S De Placido 1996 c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases J Clin Oncol 14 2702 2708 8874330 1:STN:280:DyaK2s%2FivVeitA%3D%3D
5. Mackey JR, Kaufman B, Clemens M, Bapsy PP, Vaid A, Wardley A, Tjulandin S, Jahn M, Lehle M, Jones A. Trastuzumab prolongs progression-free survival in hormone-dependent and HER2-positive metastatic breast cancer. San Antonio Breast Cancer Symposium 2006; abstract 3.
6. Nakagami K, Inoue K, Mizutani M, Hozumi Y, Fujiwara Y, Masuda N, Tsukamoto F, Saito M, Ohashi Y, Sano M, Noguchi S. Randomized Phase III study of trastuzumab monotherapy followed by docetaxel and trastuzumab versus the combination of trastuzumab and docetaxel as first-line treatment in patients with HER2 positive metastatic breast cancer. San Antonio Breast Cancer Symposium 2008; abstract 3132.
7. M Pegram S Hsu G Lewis, et al. 1999 Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers Oncogene 18 2241 2251 10327070 10.1038/sj.onc.1202526 1:CAS:528:DyaK1MXis12murk%3D
8. DJ Slamon B Leyland-Jones S Shak H Fuchs V Paton A Bajamonde T Fleming W Eiermann J Wolter M Pegram J Baselga L Norton 2001 Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N Engl J Med 344 783 792 11248153 10.1056/NEJM200103153441101 1:CAS:528:DC%2BD3MXisVGktrc%3D (Pubitemid 32222155)
9. AU Buzdar NK Ibrahim D Francis DJ Booser ES Thomas RL Theriault L Pusztai MC Green BK Arun SH Giordano M Cristofanilli DK Frye TL Smith KK Hunt SE Singletary AA Sahin MS Ewer TA Buchholz D Berry GN Hortobagyi 2005 Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer J Clin Oncol 23 3676 3685 15738535 10.1200/JCO.2005.07.032 1:CAS:528:DC%2BD2MXlslWntr8%3D (Pubitemid 46252462)
10. M Untch H Eidtmann A du Bois HG Meerpohl CH Thomssen A Ebert N Harbeck C Jackisch V Heilman G Emons D Wallwiener W Wiese JU Blohmer K Hoffken W Kuhn P Reichardt M Muscholl M Pauschinger B Langer HJ Luck 2004 Cardiac safety of trastuzumab in combination with epirubicin and cyclophosphamide in women with metastatic breast cancer: results of a phase I trial Eur J Cancer 40 988 997 15093573 10.1016/j.ejca.2004.01.011 1:CAS:528:DC%2BD2cXjt1agtrc%3D (Pubitemid 38496254)
11. M Theodoulou SM Campos G Batist E Winer L Norton C Hudis L Welles 2002 TLC D99 (D, Myocet) and Herceptin (H) is safe in advanced breast cancer (ABC): final cardiac safety and efficacy analysis Proc Am Soc Clin Oncol 21 55a abstract
12. J Cortes S Dicosimo MA Climent H Cortés-Funes A Lluch P Gascón JI Mayordomo M Gil M Benavides L Cirera B Ojeda CA Rodríguez JM Trigo J Vazquez P Regueiro JF Dorado J Baselga on behalf of the Spanish Breast Cancer Cooperative Group SOLTI 2009 Nonpegylated liposomal doxorubicin (TLC-D99), paclitaxel, and trastuzumab in HER-2-overexpressing breast cancer: a multicenter phase I/II Study Clin Cancer Res 15 307 314 19118059 10.1158/1078-0432.CCR-08-1113 1:CAS:528:DC%2BD1MXhs1eruw%3D%3D
13. T Suzuki S Minamide T Iwasaki H Yamamoto H Kanda 1997 Cardiotoxicity of a new anthracycline derivative (SM-5887) following intravenous administration to rabbits: comparative study with doxorubicin Invest New Drugs 15 219 225 9387044 10.1023/A:1005862730941 1:CAS:528:DyaK2sXnslylsLg%3D (Pubitemid 27453876)
14. Tokuda Y, Umemura S, Saito Y, Suzuki Y. Enhanced anti-tumor effect of trastuzumab combined with less cardiotoxic anthracycline, amrubicin, in HER2 positive human cancer xenografts in athymic mice. J Clin Oncol. 2008;26:abstract 14641.
15. M Marty F Cognetti D Maraninchi R Snyder L Mauriac M Tubiana-Hulin S Chan D Gries A Anton A Lluch J Kennedy K O'Byrne P Conte M Green C Ward K Mayne JM Extra 2005 Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group J Clin Oncol 23 4265 4274 15911866 10.1200/JCO.2005.04.173 1:CAS:528:DC%2BD2MXms12gs70%3D (Pubitemid 46207001)
16. M Bontenbal C Seynaeve J Stouthard M Bos H Braun FL Erdkamp G van Deijk P Schmitz I Van der Stelt-Frissen P Hamberg J Klijn 2008 Randomized study comparing efficacy/toxicity of monotherapy trastuzumab followed by monotherapy docetaxel at progression, and combination trastuzumab/docetaxel as first-line chemotherapy in Her2-neu positive, metastatic breast cancer (HERTAX study) J Clin Oncol 26 44s 10.1200/JCO.2007.11.3787 abstract 1014
17. Hayes D. Systemic therapy for HER2-positive metastatic breast cancer. UpToDate version 16.3.
18. HJ Burstein A Keshaviah A Baron R Hart R Lambert-Falls PK Marcom R Gelman EP Winer 2006 Trastuzumab and vinorelbine or taxane chemotherapy for HER2 + metastatic breast cancer: the TRAVIOTA study J Clin Oncol 24 18s 10.1200/JCO.2006.05.8677 abstract 650 (Pubitemid 46630678)
19. Fujimoto-Ouchi K, Sekiguchi F, Mori K. Preclinical study of continuous administration of trastuzumab as combination therapy after disease progression with trastuzumab monotherapy. Proc Amer Assoc Cancer Res. 2005;46:abstract 5062.
20. G Von Minckwitz C Zielinski E Maarteense P Vogel M Schmidt H Eidtmann T Cufer FE de Jongh M Kaufmann S Loibl 2008 Capecitabine vs. capecitabine + trastuzumab in patients with HER2-positive metastatic breast cancer progressing during trastuzumab treatment: The TBP phase III study (GBG 26/BIG 3-05) J Clin Oncol 26 47s abstract 1025
21. J O'Shaughnessy KL Blackwell H Burstein AM Storniolo G Sledge J Baselga M Koehler S Laabs A Florance D Roychowdhury 2008 A randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2 + metastatic breast cancer progressing on trastuzumab therapy J Clin Oncol 26 44s 10.1200/JCO.2007.11.3787 abstract 1015
22. Y Tokuda Y Ohnishi K Shimamura M Iwasawa M Yoshimura Y Ueyama N Tamaoki T Tajima T Mitomi 1996 In vitro and in vivo anti-tumor effects of a humanized monoclonal antibody against c-erbB-2 product Br J Cancer 73 1362 1365 8645580 1:CAS:528:DyaK28XksF2kt7k%3D